Trial Profile
PA21 Phase II Clinical Study in Hemodialysis Patients With Hyperphosphatemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Sucroferric oxyhydroxide (Primary)
- Indications Hyperphosphataemia
- Focus Therapeutic Use
- Sponsors Kissei Pharmaceutical
- 08 Aug 2014 New trial record